Press Releases

AAV5 DetectCDx™ detects the presence of anti-AAV5 antibodies to aid in the selection of patients eligible for the treatment ROCTAVIAN™.

Dave Shiembob, manager of ARUP Healthcare Advisory Services, guides clients with utilization best practices and real-time opportunities.

Founding members of the new Institute for Research and Innovation in Diagnostic and Precision Medicine^TM gather. In the back row, from left to right, are David P. Ng, MD; Hunter Best, PhD, FACMG; Tracy George, MD; Leo Lin, MD, PhD; and Brendan O’Fallon. In the front row, from left to right, are Salika M. Shakir, PhD, D(ABMM); Robert S. Ohgami, MD, PhD, FCAP; Benjamin Bradley, MD, PhD; and Erica Clyde. Not pictured: Tatiana Yuzyuk, PhD, ABMGG; Evan Raps, MD; Peng Li, MD, PhD; and Valarie McMurtry, MD, PhD.

ARUP Blood Services has aligned its donor eligibility assessment processes to follow recent U.S. Food and Drug Administration (FDA) guideline updates, and the changes will take effect on July 18, 2023.

ARUP’s new test is the first companion diagnostic immunoassay for a gene therapy product to receive FDA approval. FDA has issued simultaneous approval of ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), BioMarin’s gene therapy for severe hemophilia A.